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PERSPECTIVE
Designing development programs for
non-traditional antibacterial agents
John H. Rex 1,2, Holly Fernandez Lynch 3, I. Glenn Cohen 4,5,
Jonathan J. Darrow 6 & Kevin Outterson 7
In the face of rising rates of antibacterial resistance, many responses are being pursued in
parallel, including ‘non-traditional’ antibacterial agents (agents that are not small-molecule
drugs and/or do not act by directly targeting bacterial components necessary for bacterial
growth). In this Perspective, we argue that the distinction between traditional and non-
traditional agents has only limited relevance for regulatory purposes. Rather, most agents in
both categories can and should be developed using standard measures of clinical efficacy
demonstrated with non-inferiority or superiority trial designs according to existing regulatory
frameworks. There may, however, be products with non-traditional goals focused on
population-level benefits that would benefit from extension of current paradigms. Discussion
of such potential paradigms should be undertaken by the development community.
G iven the threats posed by the rise of antibacterial resistance
1,2, many responses are being
pursued in parallel, including infection prevention and control, disease surveillance,
antibiotic stewardship, and the development of new therapeutics, including so-called
“non-traditional” therapeutics.
Although there is no universal definition of “non-traditional,” Tse et al.3 define traditional
products to include “small-molecule agents that directly target bacterial components to exert a
bacteriostatic [i.e., growth prevention] or bactericidal [i.e., killing] effect,” whereas non-
traditional agents include “antimicrobial therapeutics that work through other means (i.e., not a
small molecule and/or utilizes a non-traditional target).” Non-traditional agents are diverse,
including agents that modify the microbiome, chelators that inactivate the metals needed for
bacterial enzymatic activity, nucleic acids that interfere with bacterial DNA, and antibodies or
viruses (bacteriophages) that target microorganisms or their toxins with high specificity
(Table 1). Their diversity reflects radically different mechanisms and approaches that may
improve treatment options and, in theory, delay the development of resistance.
Non-traditional therapeutics have been the subject of recent reviews3–6, symposia (22 April
2018, European Congress of Clinical Microbiology & Infectious Diseases, http://amr.solutions/
blog/eccmid-symposium-expediting-antibacterial-development-core-lessons-and-key-tools-for-
a-rocky-road), and workshops (14 June 2018, Duke-Margolis Center for Health Policy, https://
healthpolicy.duke.edu/events/understanding-development-challenges-associated-emerging-non-
traditional-antibiotics; US Food and Drug Administration, 21–22 Aug 2018, https://www.fda.
gov/drugs/newsevents/ucm606052.htm). A common theme has been the question of how
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non-traditional products can best be developed. In these discus-
sions, questions have been raised about whether existing approval
pathways are adequate, or whether there is a need for new reg-
ulatory approaches to better facilitate the development of novel
drugs that for reasons discussed below would find it difficult to
generate data adequate to support approval.
In previous decades, such questions would have been raised by
large global pharmaceutical companies using their extensive
resources to advocate for efficient development and approval
standards. But today, as recognized by numerous authors7–10,
most larger companies have discontinued their antibiotic devel-
opment programs, including recent exits by Novartis, AstraZe-
neca, Sanofi, Allergan, and The Medicines Company11,12.
As a result, most companies currently pursuing preclinical
antibiotic programs are small, entrepreneurial endeavors13. Many
are in the CARB-X portfolio (https://carb-x.org/), a government-
and charitable foundation-funded non-profit project launched in
2016 and tasked with investing up to $500 million in very early-
stage antibiotic projects around the world. Since smaller com-
panies generally lack the resources to effectively advocate for their
collective needs, two authors of this paper who have been
involved with creating and running CARB-X (J.H.R. and K.O.)
felt it was important to address pressing development issues to
ensure that the regulatory infrastructure is prepared to efficiently
evaluate these new technologies and advance them through
development and approval.
In this Perspective, we conclude that (a) the idea of a non-
traditional product has only limited relevance to regulatory
decision-making; (b) most products classified as non-traditional
can and should be developed within the existing regulatory fra-
mework using assessment measures based on how the therapeutic
agent affects the way the treated individual feels, functions, or
survives; and (c) there are innovative product types with pri-
marily population-level and future benefits that may warrant
further discussion regarding how these benefits can best be
incorporated into the drug evaluation paradigm.
The idea of “non-traditional” has limited utility
The definition by Tse et al.3 includes as non-traditional both
products with non-traditional properties (e.g., lacking intrinsic
antibacterial activity on their own and hence neither bactericidal
nor bacteriostatic) as well as antibacterial products that are not
small molecules. This definition can be improved by dis-
aggregating it into its two components: non-traditional molecular
structures and non-traditional product goals (Table 2).
Distinguishing traditional and non-traditional molecular
structures separates small-molecule antibiotics from larger
molecules or radically different products. Typical small-molecule
drugs are completely characterized chemically, and usually have a
molecular weight less than ~1000 Da. Non-traditional products
such as bacteriophages or genetically engineered antibodies are
usually much larger and sometimes not readily visualized without
the aid of computer modeling. In some cases, the product is a
mixture of substances that cannot easily be described except by
reference to functional characteristics (e.g., polyvalent antisera
characterized by ability to neutralize a target). There are also non-
traditional products that are radically different, such as charcoal-
based absorbents that selectively sequester antibiotics in the lower
gastro-intestinal tract to reduce disruption of healthy intestinal
flora14, or lipid-based products that absorb bacterial toxins
without directly affecting bacterial growth15.
The idea of traditional vs. non-traditional product goals offers a
different comparison. Traditional goals encompass prevention
Table 1 The wide range of non-traditional antimicrobial agents
Category Essential mechanism (breadth of effect)a Examples of approvedb products
Antibiotic-sequestering products or
antibiotic-degrading enzymes
Physical binding or destruction of antibiotic molecules that
reach the large bowel, thereby limiting damage to the
microbiome and reducing risk of Clostridium difficile-related
diarrhea (Broad) and the spread of antibiotic residue in the
environment
No approved examples
Antibodies Inactivation of a pathogen, a virulence factor, or a toxin
(Narrow)
Antisera to the toxins that produce the
clinical syndromes of anthrax, diphtheria,
botulism, and tetanus.
Bacteriophage (both wild-type and
engineered)
Direct lysis of target bacteria (Narrow) No approved examples
Host immune response modifiers
(stimulating and immunosuppressive)
Augmenting or suppressing host immune response to
modify course of infection (Broad)
Interferon-gamma, G-CSF
Lysins Direct lysis of target bacteria (Narrow) No approved examples
Metal chelation Inactivation of key bacterial enzymes by chelation of zinc,
manganese, or iron from the bacterial enzyme (Broad)
No approved examples
Microbiome and probiotics Modification of microbiome to eliminate or prevent
carriage of resistant or pathogenic bacteria (Narrow
to broad)
No approved examples
Nucleic acids, antibacterial (CRISPR and
related)
Anti-sense or target destruction used to interfere with
bacterial DNA (Narrow)
No approved examples
Nucleic acids, anti-resistance Direct killing of bacteria by nucleic acids (Narrow) No approved examples
Peptides, antibiofilm Peptides based on innate defense peptides (defensins) or




Peptides, innate host defense
Toxin sequestration or removal Removal of bacterial toxins may modify the course of
infection (might be Broad or Narrow)
No approved examples
Vaccines Prevention of infection by induction of an antibody
response that interferes with bacterial pathogenesis
(Narrow)
Many examples (e.g., vaccines for S.
pneumoniae)
aBreadth of effect: Narrow= activity is usually limited to a single species of bacteria and hence likely to require targeting via a diagnostic; Broad= breath of activity might be sufficiently broad to permit
empiric use against the typical range of bacteria causing a given syndrome. bApproved in the US or EU. (Categories adapted from refs. 5 and 3)
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(vaccines) and direct effects on bacterial growth, including killing
of bacteria (therapeutics). By contrast, non-traditional goals,
include reducing the impact of bacterial toxins; hindering the
formation of biofilm, a dense, extracellular matrix produced by
some microbes that can be difficult for antibiotics or the immune
system to penetrate; preventing colonization with organisms that
could propagate antibiotic resistance genes; and improving/
restoring microbiome diversity. As with traditional antibiotics,
which both treat the individual and simultaneously reduce risk of
transmission to others, new antibiotics aimed at non-traditional
goals may produce both individual benefit (e.g., if an individual
does not become colonized with Salmonella, then infection due to
Salmonella would only occur if initial exposure led immediately
to infection), and also benefit to others (e.g., if an individual is not
colonized with Salmonella, then transmission to others via
environmental shedding is not possible)16. But unlike traditional
products intended for and developed based on measures of
individual benefit, some products are being developed primarily
for their population-level or future benefits.
Whereas non-traditional structures and some non-traditional
goals are adequately served by current regulatory paradigms,
progression of products with non-traditional goals focused on
population-level benefits may require extension of current para-
digms, as discussed below.
Four instructive development categories (STAR). The value of a
new antibiotic product is determined by its ability to achieve a
particular therapeutic outcome or to achieve public health goals;
it is not dependent on its structural classification as traditional or
non-traditional. To see this, categorizing both traditional and
non-traditional antibiotic products into four development
archetype categories of Standalone, Transform, Augment, and
Restore (STAR, Fig. 1) helps identify relevant regulatory and
ethical considerations:
● Standalone: Products in this category are effective as
monotherapy. Essentially all traditional small molecules fit
here, but direct-acting bactericidal products with non-
traditional structures (e.g., bacteriophage) could also be
standalone. Vaccines will generally fit here.
● Transform: The product transforms (or extends) the range of
an existing product to enable action against microorganisms
not previously susceptible to the existing product. For
example, efforts are underway to use polymyxin B analogues
to allow drugs currently effective only against Gram-positive
bacteria to enter and act on Gram-negative bacteria as well17.
To date, there are no approved products in this category.
● Augment: The product augments or improves on the activity
of an otherwise active and effective antibiotic. Products
seeking to reduce bacterial virulence or neutralize a bacterial
toxin are an example of this category and have to date been
polyclonal or monoclonal antibodies18,19. Approved examples
of this category are limited to a small number of products that
neutralize toxins in diseases where the toxin (rather than the
bacterial burden) is the primary cause of the clinically
apparent disease. Examples include a monoclonal antibody
(raxibacumab) to a toxin of Bacillus anthracis20, a polyclonal
equine antiserum for toxins of Corynebacterium diphther-
iae21, antisera for toxins produced by Clostridium botulinum
(polyclonal equine and polyclonal human antisera)22, and a
polyclonal human antiserum for toxins produced by Clos-
tridium tetani23. With these products, a standard antibacterial
is often used to eliminate carriage of the toxin-producing
organism and thereby both stop production of toxin and
reduce transmission to others of the organism, but the anti-
toxin antibodies have a strong activity independent of
clearance of the bacteria. In a related but not identical
fashion, a monoclonal antibody to a toxin of C. difficile
(bezlotoxumab) also exists but its primary effect is to reduce
recurrence following control of active disease by a standard
antibiotic therapy24.
● Restore: The product restores the activity of an existing
product that has lost utility due to development of resistance
(e.g., evolution allowing the bacteria to produce beta-
lactamase, an enzyme that breaks down beta-lactam anti-
biotics to render them ineffective). Several products in this
category have been approved (e.g., amoxicillin combined with
the beta-lactamase inhibitor clavulanic acid).
Note that three of these categories (Transform, Augment, and
Restore) are intrinsically combinations in which the novel agent
also could be described as a potentiator, enhancer, or adjuvant of
the product with which it is paired. These terms are non-specific,
however, and have been applied interchangeably25. The terms
Transform, Restore, and Augment better distinguish the function
of the various types of products currently being developed, and
are therefore preferable.
Four development categories: implications. Products in all four
of the STAR categories can be developed using current regulatory
approaches for establishing non-inferiority or superiority (see
Examples
• Traditional
  small molecule
• Phage




  factor inhibitor
  or anti-toxin
  antibody








  activity from colistin
  + approved Gram-
  positive antibiotic
Fig. 1 STAR: The four novel product categories. Both traditional and non-
traditional antibiotic products can be placed into one four fundamental
categories: Standalone (effective as monotherapy), Transform (extends the
range of activity of an existing product), Augment (enhances the effect of
an otherwise effective product), and Restore (rejuvenates the activity of an
antibiotic that otherwise lost utility)
Table 2 Two categories of traditional (T) vs. non-traditional (NT)
Traditional (T) Non-traditional (NT)
Structure Typical small molecule Bacteriophage, lysins, (monoclonal) antibodies, charcoal, and oligonucleotides
Development goal Treatment or prevention of a standard
infection
Other goals, such as prevention of development/acquisition of resistance, improving/
restoring microbiome status, and slowing the spread and resistance in the population
at large
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Box 1), although problems of dose selection (Box 2) and patient
enrollment may still occur.
While superiority trials provide stronger evidence of efficacy, in
many infection settings the only plausible trial design is non-
inferiority (Box 1). In particular, non-inferiority trials are likely
appropriate for the Standalone, Transform, and Restore categories
(Table 3). In trials of these types of agents, the new agent will be
compared to an existing control agent in the so-called usual drug
resistance (UDR) setting26 in which resistance is not extreme and
one or more reliably active control agents can be used as
standard-of-care comparators. The UDR setting is used because
although preclinical evidence may suggest that the novel therapy
would offer incremental therapeutic benefit specifically in patients
harboring resistant bacteria, it would be unethical to randomize
such patients to a control agent known or predicted to be
ineffective due to resistance, particularly where there is a
substantial risk of morbidity or mortality27,28. Yet in the UDR
setting, the fact that the control is a therapy that is safe and highly
effective in curing most patients in the population makes it
unlikely that a new product could demonstrate superiority—what
is superior to achieving patient cure?
Developers of new drugs for resistant pathogens thus face a
conundrum. Ideally, they would develop data on the new product
in the face of resistant pathogens before the onset of a widespread
public health concern. But until such an outbreak, there will be at
least one existing reliable agent for the UDR bacteria currently
extant. That such reliable agents exist is desirable for society, of
course, but what it demands is that infected patients be treated
either with a reliable agent or something in equipoise with it.
Even in those worrisome scenarios in which there is no currently
Box 1 | Non-inferiority vs. superiority trial designs
All pharmaceutical products must (a) show which individuals can benefit from the product, (b) demonstrate a way to identify those individuals, and (c)
document the benefit received from the product. Clear answers to these questions are required for product approval and acceptance. To achieve this,
one of two types of trial designs can be used55–59. In a superiority trial, the goal is to show that a product, “NEW,” is measurably superior to “EXISTING”
or to a placebo. In a non-inferiority trial (sometimes formerly referred to as an “equivalence trial”), the goal is to show that NEW has efficacy similar
(within the bounds of a pre-specified non-inferiority margin) to that of EXISTING. Each design has strengths and weaknesses.
Superiority trials are more compelling and are preferred whenever possible. Because they demonstrate that NEW improves on EXISTING (or on
placebo), a positive outcome shows simultaneously: (1) the advantage of NEW, and (2) that the group of individuals are likely to benefit from NEW can
be identified.
In contrast, a non-inferiority demonstration of similar outcomes between NEW and EXISTING could mean either that (a) NEW and EXISTING both
indeed had similar benefits subject to the non-inferiority margin and statistical limits of the study, or (b) NEW and EXISTING both did nothing and
hence appear to have similar efficacy, which could occur, for example, if inadequate screening led to the enrollment of subjects with viral pneumonia in
a trial intended to test two treatments for bacterial pneumonia. In practice, there are many ways that non-inferiority trials can produce flawed
results28,59.
Although superiority trials would thus seem the natural choice, the need to show superiority becomes a weakness in the setting of bacterial infections
given their acute onset, high morbidity and mortality risk, lack of timely precision diagnosis, and the importance of immediately beginning a reliable
therapy27,28. Except for trivial situations, acute infections are associated with striking risks when not treated promptly and properly. It is thus imperative
to offer effective therapy if at all possible. However, when a safe and highly effective therapy serves as the comparator in a trial, it is unlikely that a new
product would more effectively clear an infection than the comparator. Furthermore, efforts to control the spread of drug-resistant infections make it
more difficult to enroll the patients needed for a superiority design trial. While it might be hoped that modern molecular diagnostics could solve this
problem, practical considerations reduce their impact. Consider, for example, an uncommon bacterium of interest (perhaps a specific species or
perhaps a form of resistance) that is seen in only 1% of cases of a given syndrome. Even if diagnostics could rapidly identify cases of interest, 100 cases
must be screened to find a single case of interest. As diagnostic tests never have perfect sensitivity or specificity, the required number to screen would
be even higher.
The speed with which most infections progress also works against case finding. Unlike rare genetic disease or tumors where there is time to refer to a
specialty center, acute infections progress to produce substantial morbidity and mortality over hours to a few days. It is standard practice to initiate
“empirical therapy” within a few hours of diagnosis, that is, treatment with an antibiotic expected to be effective based on a clinician’s educated guess
as to the identity of infectious agent, before the particular pathogen has been more robustly identified with a diagnostic test. With the exception of a
small number of chronic bacterial infections, this means that the patient with the rare bacterium must present at a facility already running the relevant
trial. If empirical therapy proves adequate to eradicate the organism, the ability to demonstrate the activity of the test product is further diminished.
Thus, superiority designs work ethically and methodologically only where there is truly no proven alternative. This may be the case in truly grave public
health circumstances involving resistant pathogens, but once a novel effective therapy is created, superiority designs again become difficult.
In contrast, non-inferiority designs allow trials to proceed without requiring resistance to develop to the point that effective therapy is widely
unavailable. The real value of the new agent resides in its theorized but not yet fully proven utility to future patients (Table 4 and ref. 59).
Box 2 | Dose selection for products lacking direct antimicrobial activity
An important challenge could arise for any of the four categories depending on the product. Antibiotic development relies heavily on dose selection
based on prediction from animal models of the antibiotic exposures (pharmacokinetics (PK) and pharmacodynamics (PD)) likely to be efficacious60,61.
Traditionally, the concept of minimum inhibitory concentration (MIC) has been central to the mathematical underpinnings of PK-PD. The MIC is the
minimum concentration of a drug that prevents visible growth in a laboratory test tube or Petri dish. It is also used as a key element when determining
the drug concentration levels required to obtain an effective response62. Given the extensive experience with MIC-based PK–PD to predict efficacy63,64,
a demonstration that efficacy should follow from a given drug concentration65 can support approval of an antibacterial agent based on a single-clinical
trial28.
Some non-traditional products in development lack an MIC, such as agents designed to absorb bacteria-produced toxins while leaving the bacteria
themselves unaffected. A compelling demonstration of clinical activity for such products may require more clinical data than for products with
supportive MIC-based PK–PD evidence. This challenge might be less for products designed to lower the MIC of an existing drug when part of a
combination25,66.
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reliable agent for UDR, the development of the first new product
that addresses resistance resets the standard of care, as the new
agent becomes the new reliable intervention.
The result is that in the (desirable) presence of a reliable agent
for current UDR bacteria, development of new antibiotics must
rely on non-inferiority design in the UDR setting. Although the
pivotal UDR trial does not directly establish evidence of
effectiveness in populations for which existing antibiotics are
less effective or ineffective, two lines of logic suggest the new
agent is likely to be effective in a future setting when currently
reliable agents fail. First, and generally limited to agents acting by
a mechanism different from that of existing agents, emergence of
resistance to the currently reliable comparator will usually have
no impact on the microbiologic activity of the new drug: the new
drug is expected to retain the activity demonstrated in the UDR
study whether or not the older drug retains its activity (i.e., cross-
resistance is unlikely). Second, data in second-line non-UDR
settings in which older agents have failed can often provide at
least a small-scale demonstration of the potential of the new
compound.
While, for the reasons discussed, non-inferiority designs are
often necessary for products in the Standalone, Transform, and
Restore categories, a demonstration of superiority becomes
preferable and perhaps required for Augment and sometimes
for Restore (as discussed below). To understand this, consider a
hypothetical non-traditional product “AUGMENT” designed to
enhance immune control of an infection when given with
“EXISTING,” a currently approved antibiotic. Regulations
generally require that each component of a fixed-combination
product contribute to its claimed effects, such as enhancements to
the safety or effectiveness of the principal active component29. A
demonstration of similar efficacy (non-inferiority) between two
trial arms would fail to meet this requirement: only by showing
that AUGMENT+ EXISTING improves on EXISTING is it
demonstrated that the new component of AUGMENT con-
tributes to the product’s claimed effects.
Given the high (usually ≥ 80–90%) success rates with modern
antimicrobials, the requirement to demonstrate further increased
efficacy is a very challenging hurdle, although a new drug could
correct some defect in an older one. For example, AUGMENT
might offer incremental value by simplifying dosing or reducing
the side-effects of EXISTING as some formulation improvements
of traditional antibiotics have done. But absent a plausible
additional clinical benefit, Augment developers will struggle to
justify reasons to undertake clinical trials.
A hurdle similar to that for Augment may also occasionally
arise for Restore. Consider a novel beta-lactamase inhibitor (BLI)
that protects a beta-lactam (BL) antibiotic from destruction by
beta-lactamase enzymes. Similar to the problem discussed for
AUGMENT+ EXISTING, the value of BLI+ BL combination is
only seen when the infecting organism is resistant to the BL but
susceptible to the BLI+ BL. If it is easy to find such organisms,
then a study of BLI+ BL vs. an existing product of a different
class that has retained activity (usually a carbapenem, the typical
reliable drug of current development programs for UDR Gram-
negative bacteria) will show the BLI+ BL to work when the BL
alone would have lacked activity. If, however, the relevant bacteria
are very rare, it may be almost impossible to show the advantage
of the combination.
Non-inferiority designs can therefore be used to evaluate
products in the Standalone, Transform, and Restore categories
without waiting for resistance to develop such that effective
therapy is unavailable (Table 4). Although the primary benefit of
such products derives from their theorized abilities to address
future resistance, perhaps as demonstrated by laboratory or
animal data, the non-inferiority clinical design means that robust
evidence of effectiveness in such future human populations is not
available at the time of approval.
Normal regulatory requirements apply to non-traditional
products. Given their intriguing potential properties (Table 1),
it is sometimes suggested that non-traditional products could
perhaps be exempt from the normal regulatory approval rules.
However, there is typically no reason for such products to be
exempt from the usual requirements to demonstrate safety and
efficacy. For example, if an effect on a clinical outcome cannot be
used, efficacy could perhaps be established by showing an impact
Table 4 Why superiority is pursued in some areas but not routinely available for anti-infectives
Why not superiority? Migraine Cancer Infection
1. Durable cure is routine No No Yes
2. Placebo is routinely acceptable Yes No No
3. Transmissible resistance arises, thus new agents always needed No No Yes
4. New agents are really for use… Today Today Tomorrow
In the table, the constraints for developing new agents for migraine, cancer, and infection are considered. For migraine, delayed treatment is painful but has no long-term consequences, and thus it would
be ethical to ask a study participant to enroll in a trial where one arm was only placebo (or delayed therapy). In the case of cancer, placebo is not acceptable but durable cure is not routine and there
remains substantial opportunity for improvement on current therapies. For anti-infectives, however, durable cure is expected as routine and placebo (or deliberate use of ineffective therapy) is not ethical
if there is any alternative whatsoever. The use of non-inferiority designs in infection offers a way to proactively address the need to produce new agents to address emerging resistance and to complete
such development programs before resistance is sufficiently widespread that the current agents are frequently ineffective
Table 3 Development options for the four categories
Design options Would data from a non-inferiority study be
adequate for approval?a
To what extent is a demonstration of




Restore Yes Usually optional
aIs it possible to achieve initial approval by studying the product in a head-to-head non-inferiority study in which the novel product is compared with an existing agent in a usual drug resistance (UDR)
setting where the comparator agent has retained activity?
bRecognizing the conflicting tension around use of superiority studies for approving new agents (see text), does demonstration of the value of the novel agent effectively require a superiority study?
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on a surrogate outcome measure (such as microbiome change).
But, such an outcome measure would be held to the standard of
“reasonably likely to predict clinical benefit” under the FDA’s
accelerated approval pathway30–32. Unless such standards for
surrogate markers of efficacy are met, evidence of impact on a
novel endpoint might be hypothesis-generating but could not be
used to support approval.
Non-traditional goals: the issue of population-level benefits
Traditionally, antimicrobial products have been developed to
provide direct benefits to the individuals receiving treatment.
Although these products have always produced positive extern-
alities in the form of reduced opportunities for transmission to
third parties33, companies have recently begun to develop pro-
ducts designed to benefit third parties while offering only occa-
sional benefits to the treated individual.
For example, a product may focus on preventing colonization
(and hence seeking to reduce the risk of infection) rather than
treating clinical symptoms after invasive infection develops. At a
recent workshop on non-traditional products (https://www.fda.
gov/drugs/newsevents/ucm606052.htm), participants considered
such a hypothetical product: “Z-3,” postulated to prevent acqui-
sition of Metallo-Beta-Lactamase-producing (MBL-producing)
Gram-negative bacteria in gut flora. MBL is an enzyme that can
degrade certain antibiotics, including carbapenems, and bacteria
producing it are considered highly antibiotic-resistant. By pre-
venting acquisition of MBL-producing bacteria, Z-3 could both
reduce the risk of an infection due to such an organism as well as
minimize opportunities for the MBL gene to spread.
As there are relatively few reliable agents for treating infections
due to MBL-producing bacteria, the second benefit (reduced
transmission) has public health implications. Although Z-3 would
not prevent infections associated with gut flora such as UTI and
appendicitis, such infections should not be due to MBL-producing
bacteria but rather to less difficult-to-treat strains. Thus, Z-3 may
offer some benefit to the treated person, but its potentially greater
value comes from the public health benefit to others through
reduced transmission of the difficult-to-treat bacteria.
Measuring those public health benefits is challenging. In tra-
ditional vaccine trials, an agent’s value is measured by reduction
in observable clinical infections directly in the individuals
receiving the vaccine. This effect is sometimes but not always
mediated in part by preventing colonization34,35. In the case of Z-
3, the major emphasis would be on preventing colonization with
MBL-producing bacteria and extrapolating from lowered colo-
nization rates to predict both individual and population-level
clinical benefit, as clinical infections caused by non-MBL-
producing bacteria in individual patients may not be reduced.
Preventing colonization with MBL-producing bacteria by Z-3
could offer some benefit to treated individuals by reducing the
risk of developing invasive MBL-producing bacterial disease, but
the individual benefit might be quite small due to the infrequency
of such colonization and the fact that, even if colonized, the
individual might not develop invasive disease.
It might be possible to resolve these difficulties by developing and
validating a surrogate marker, but that is not an easy task and the
most obvious surrogate (lack of detectable colonization with resis-
tant strains) is not acceptable due to the inability to demonstrate
that it is reasonably likely to predict clinical benefit. In studies to
date, the linkage between elimination of carriage and subsequent
disease has been inconsistent36,37, presumably both because it is
technically difficult to prove absence of carriage in every possible
nook and cranny of the human body, and because pathogens can be
acquired at any time from new environmental exposure. Thus, a
2013 guidance from EMA38 states that “Indications that relate to
the reduction or eradication of a pathogen from a specified body
site are not acceptable unless the microbiological effect of active
treatment has been shown to result in a measurable clinical benefit.”
To our knowledge there is no exact parallel statement in FDA
guidance, but the need for a surrogate marker to convincingly
predict a clinical outcome is apparent in FDA-supported docu-
ments that discuss degrees of validation of endpoints31,32 as well
simply having strong face validity.
This leads to a significant challenge when the primary benefit
of a proposed product accrues only in a much larger population
than those directly treated. This raises important questions about
how pivotal trials for a product like Z-3 should be designed, and
to what extent regulators should take into account positive
externalities that benefit both current and future populations not
receiving direct interventions in the clinical study33. These pro-
ducts also pose challenges related to market demand that may
prove to be more difficult to overcome than the regulatory
considerations.
Research ethics
In parallel to the scientific and regulatory issues that have been
discussed so far, there are also ethical considerations that must be
addressed.
First, and most fundamental, is the question of whether it is
ethically acceptable to carry out non-inferiority trials when
developing new antimicrobial agents. Outside a trial, those who
might be asked to enroll would be treated with a reliable drug, i.e.,
an existing effective agent (assuming their infection is not resis-
tant to all available therapies). Within the trial, they would be
randomized either to the novel intervention or the reliable
standard-of-care drug. However, in a non-inferiority trial, that
novel intervention is not hypothesized to leave the participant
better off than he or she would have been outside the trial, given
that superiority is not expected. Instead, the only hypotheses are
that participants randomized to the intervention arm of the trial
could do as well as they would have done outside the study (best
case) or potentially worse. Equipoise may still be satisfied in this
scenario, as the expectation is that the novel intervention will be
an acceptable clinical substitute for the established older drug
such that no participant is made knowingly worse off as a result
of randomization39. Nonetheless, except for those individual
participants who turn out to be infected with a resistant pathogen,
enrollment entails an entirely risk-based proposition compared to
accepting standard care outside the study.
Non-inferiority trials have been criticized on these grounds,
particularly on the basis that it is inappropriate to ask participants
to accept such risks for the moderate (or even low) social value
traditionally associated with non-inferiority design40,41. These
criticisms are inapposite here, however. Unlike non-infectious
disease products approved based on non-inferiority trials, new
antibiotics approved based on such trials offer the promise of
substantial social value if they are believed, based on non-clinical
evidence, to be able to address future resistant infections
(potentially, including those occurring in current study partici-
pants). Moreover, even if the new intervention is somewhat
inferior to the proven effective current product, it could still be a
useful treatment option in the face of future resistance when the
current product is no longer effective.
Thus, despite their non-inferiority designs, these trials are not
focused on current non-inferiority, but rather future superiority
(Table 4). Although it may be important to take steps to reserve
new interventions for use only in the future as a matter of
stewardship, that is for regulators, prescribers, and payers to
consider42,43; it does not dictate whether the study itself evaluates
a worthwhile clinical question.
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Hypothetically, it would be ideal to instead conduct superiority
trials exclusively in patients with infections resistant to available
therapies, since they would potentially be able to derive direct
clinical benefit from study participation and the resulting data
would be stronger. However, as noted above, the logistics of such
a design may be impractical until such point as the fully drug-
resistant bacteria are endemic (see Box 1), which would represent
a global public health calamity. In other words, it would be
unethical to wait to develop novel antibiotics until resistant dis-
eases become more widespread—and it is only at that point that
superiority trials might be feasible.
For these reasons, if we conclude that these are new products
worth having because they have sufficient social value44, the
impracticability of superiority designs and the fact that much of
what is worrisome about non-inferiority designs is absent in this
context means that non-inferiority designs may be acceptable.
But the question remains: is it justified to ask patients facing
serious infection to risk treatment with an investigational product
in a non-inferiority trial when they likely would be adequately
treated by a reliable drug in the UDR setting and are therefore not
likely to be made better off by participation? In other words, is
equipoise—which focuses on the avoidance of inferior treatment
—sufficient? The short answer is yes. This is because there is no
ethical requirement that research have the potential to make
participants better off compared to how they might fare outside a
study, or even to offer them any possibility of direct benefit at all.
If trials posing risks in the absence of the potential for superior or
direct benefit were necessarily unethical, it would be impossible to
conduct Phase I trials in healthy participants—or any non-
therapeutic research. Instead, ethical obligations to study parti-
cipants demand minimizing the risks to which they may be
exposed, ensuring that remaining risks are justified by potential
benefits, and protecting participant autonomy by securing ade-
quate informed consent45,46. Each responsibility could be satisfied
in this context.
First, if a non-inferiority study was designed so that (a) the
dose of the novel agent is chosen to maximize its likely efficacy
based on preclinical data and (b) individuals failing either study
arm are promptly moved to a salvage therapy, the risk of
inadequately treated infection or rapid progression would be
addressed and the risk of serious harm to study subjects mini-
mized. Thus, it would be possible to comply with the ethical
standard espoused in the Good Clinical Practice guidelines (Point
2.3 of ICH E6 (R1)) that the “rights, safety, and well-being of the
trial subjects are the most important considerations and should
prevail over interests of science and society.”
Second, risks to individual trial participants are often justified
by the prospect of benefit that would accrue only or primarily to
future patients44,47. Indeed, Miller and Joffe39 argue that
“risk–benefit assessment, geared to the purpose of clinical trials in
developing knowledge to inform health-policy decisions for
populations of patients,” is more important to assessing a trial’s
ethical permissibility than the presence of equipoise as tradi-
tionally understood. Moreover, U.S. regulations governing
research with human subjects explicitly acknowledge that study
risks and benefits may not necessarily accrue to the same indi-
viduals, permitting Institutional Review Boards to approve pro-
posed research when “[r]isks to subjects are reasonable in relation
to anticipated benefits, if any, to subjects, and the importance of
the knowledge that may reasonably be expected to result”
(emphasis added)45,46.
Of course, this can be a challenging calculation for research
ethics review committees, especially considering that there is no
well-accepted upper threshold of permissible research risk48 and
reasonableness standards are notoriously fuzzy. It can be facili-
tated, however, by using “component analysis,” which
distinguishes between research procedures that offer the prospect
of direct clinical benefit to participants and those that are non-
therapeutic49. In the context of a non-inferiority trial of a novel
antibiotic, infected participants are offered the prospect of direct
benefit and expected to fare as well as they would in standard
care, while the risk that they will not—if minimized as described
above—is likely justified by potential public benefits of having a
new effective therapy available in the armamentarium against
resistant bacteria. Thus, we anticipate that this type of research
can easily satisfy required risk–benefit analysis.
Finally, it is important to explain to potential participants that
they could be treated outside the trial with an agent predicted to
be safe and effective, absent resistance, and that by enrolling they
would face risk predominantly for the benefit of others41,50–52.
Some may be willing to do this altruistically and some may need
financial incentives, but both can be acceptable motivations53,54.
Assuming there is reason to believe there would be enough
willing participants to adequately enroll a trial—an essential
ethical assumption, as otherwise the risks to participants could
not be outweighed by potential social benefits because it would
not be possible to answer the study questions—non-inferiority
designs to develop new interventions to gird the future stock of
available therapeutics can satisfy essential ethical criteria.
It is essential to note, however, that the social benefit that is
ethically required of research is not guaranteed simply by
developing a theoretically useful novel antibiotic. If patients
would not have adequate reason to take that product once
approved, the potential for social benefit will be dramatically
limited, raising a range of practical and ethical concerns pre-
liminary to any questions regarding appropriate regulatory
pathways for approval.
Consider again the hypothetical product Z-3, theorized to
prevent human acquisition of non-pathogenic MBL-producing
bacteria. Prevention typically depends on patients reasonably
anticipating the implications for them of clinical infection by a
pathogen. For example, unless they are required to be vaccinated
by their employer, people are likely to receive the influenza
vaccine because they anticipate they are likely to be exposed to
the virus and do not wish to suffer from infection. From the
individual perspective, it is often only an incidental benefit that
their contacts may also be protected by their vaccination.
For a product like Z-3 to be taken up in practice, individuals
would have to anticipate a sufficient individual benefit stemming
from a reasonable likelihood of clinical infection due to MBL-
producing bacteria. Otherwise, they are not likely to use a product
to prevent such infection simply for the public health benefit to
others. Although state governments have the authority to impose
public health measures (e.g., preventative interventions such as
vaccination), such authority is permissible only for compelling
and direct public health benefits of a sort not likely for a product
like Z-3. Therefore, use of the product will have to be motivated
by patients themselves rather than some external mandate. Per-
haps individuals living in or visiting certain countries in which
bacteria susceptible to Z-3 are more prevalent would have ade-
quate concerns to motivate its use for their own benefit, but they
would have to be convinced that the risks are sufficiently great
that they will become infected and suffer clinical sequelae from
such bacteria, which is not something that can be taken for
granted.
Clinical trials to evaluate a product like Z-3 would be ethically
acceptable only if there is an adequate population likely to utilize
the product once approved and marketed. As described above,
such trials would otherwise subject participants to risks and
burdens that could not be justified by their ostensible social value.
Note that this stands in contrast to novel antibiotics intended to
treat individual patients when they lack other options for quelling
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a current infection with resistant bacteria; these patients would
clearly have reason to take such a drug for their own benefit, if
approved.
Assuming there is a plausible patient population and path to
approval for Z-3, along with sufficient numbers of willing parti-
cipants for adequate clinical trials, the primary ethical con-
siderations arising for trial participants would be risk
minimization, adequate balance of risks and potential benefits to
subjects and society, and informed consent, as discussed above
with regard to non-inferiority design. However, the questionable
clinical utility and acceptability of a product like Z-3 is likely to be
the most substantial hurdle to its development, due to the modest
direct benefits to the patient and difficulties creating a market for
more diffuse benefits to public health. Designing a trial that can
capture both the direct and population-level benefits of a product
like Z-3 will not be simple and may require techniques such as
cluster randomization to allow measurement of the population
benefits of lower resistance rates in, for example, hospitals using
vs. not using the product. Approval pathways could also be
challenging given measurable benefits primarily at the population
rather than individual level, but this is a secondary concern
behind the development issues related to an uncertain market for
these products and associated ethical concerns for justifying
clinical trials.
Summary
The idea of non-traditional antibiotic products has generated
substantial interest because of the potential for radically different
mechanisms of action that could address unmet needs. These
products have potential value for society, but investment in these
products may be suboptimal if the regulatory requirements for
demonstrating safety and efficacy are not clear.
Developers of non-traditional antibacterial agents should not
expect to bypass established regulatory and ethical standards.
Rather, most non-traditional products fall readily into one of the
four arms of the STAR paradigm, and can be tested using existing
non-inferiority- or superiority-based trial designs under existing
regulations applicable to traditional small-molecule products.
While most antibiotics are currently approved based on non-
inferiority designs27,31, some non-traditional products can best
(or must) show their value via a demonstration of superiority
over existing products. This challenge is most evident in the case
of products in the Augment category where a partner therapy (or
the antibacterial standard of care) has retained its activity, but
where it is hoped that efficacy can be improved. Here, the core
test is of the combination vs. the existing product alone, and the
combination will be required to be superior. The existing product
must be fully dosed and expected to yield its baseline level of
efficacy. Given the good efficacy of current tools, superiority is
predicted to be difficult to demonstrate. It thus seems unlikely
that this pathway will be routinely feasible and there is no obvious
solution for this problem — if the partner compound is highly
efficacious, then simply showing similar efficacy in combination
with an Augment agent does not provide a reason to use the new
product in the absence of other information.
Turning to the question of non-traditional goals, the primary
benefit in all the trials just discussed will be observable at the level
of the individual treated with the new agent, in some cases based
on newly validated surrogate endpoints. A challenge remains,
however, for products with the primary potential for population-
based benefits, including benefits to future generations. Although
these may be important products from a public health perspec-
tive, if they are insufficiently attractive to the patients who would
need to take them because they are insufficiently relevant to their
individual health, development is likely to be stymied by practical
and ethical issues even before the challenges of regulatory
approval arise. For these products, it will be important to identify
an appropriate clinical market in which individual benefit is
sufficiently large to motivate use.
In summary, the idea of a non-traditional product has only
limited relevance to regulatory decision-making as most products
classified as non-traditional can and should be developed within
the existing regulatory framework. That said, innovative product
types with primarily population-level and future benefits can be
envisioned and these would seem to warrant further discussion
regarding how such benefits can best be incorporated into the
drug evaluation paradigm.
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